Richard A. Moscicki, M.D.'s post explains how FDA receives more than 1,000 expanded access applications a year and calls the Navigator the first consolidated starting point for researching available investigational therapies. "The last thing a patient and their loved ones coping with serious or life-threatening illness needs is an overly burdensome process... the Navigator helps to reduce that burden."